Intra-Cellular Therapies Statistics
Total Valuation
FRA:7IR has a market cap or net worth of EUR 594.98 million.
Market Cap | 594.98M |
Enterprise Value | n/a |
Important Dates
The last earnings date was Friday, July 18, 2025.
Earnings Date | Jul 18, 2025 |
Ex-Dividend Date | Jul 30, 2025 |
Share Statistics
Current Share Class | 25.54M |
Shares Outstanding | n/a |
Shares Change (YoY) | +0.39% |
Shares Change (QoQ) | +0.03% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 18.88M |
Valuation Ratios
The trailing PE ratio is 10.58.
PE Ratio | 10.58 |
Forward PE | n/a |
PS Ratio | 4.81 |
PB Ratio | 1.60 |
P/TBV Ratio | 1.60 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 15.67%.
Return on Equity (ROE) | 15.67% |
Return on Assets (ROA) | 1.83% |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | n/a |
Revenue Per Employee | 515,008 |
Profits Per Employee | 234,375 |
Employee Count | 240 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, FRA:7IR has paid 19.75 million in taxes.
Income Tax | 19.75M |
Effective Tax Rate | 25.99% |
Stock Price Statistics
The stock price has decreased by -20.55% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -20.55% |
50-Day Moving Average | 22.75 |
200-Day Moving Average | 25.74 |
Relative Strength Index (RSI) | 39.67 |
Average Volume (20 Days) | n/a |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 5.51 |
Income Statement
In the last 12 months, FRA:7IR had revenue of EUR 123.60 million and earned 56.25 million in profits. Earnings per share was 2.19.
Revenue | 123.60M |
Gross Profit | 123.60M |
Operating Income | 76.51M |
Pretax Income | 76.00M |
Net Income | 56.25M |
EBITDA | n/a |
EBIT | n/a |
Earnings Per Share (EPS) | 2.19 |
Balance Sheet
The company has 254.31 million in cash and 368.89 million in debt, giving a net cash position of -114.57 million.
Cash & Cash Equivalents | 254.31M |
Total Debt | 368.89M |
Net Cash | -114.57M |
Net Cash Per Share | n/a |
Equity (Book Value) | 371.34M |
Book Value Per Share | 14.54 |
Working Capital | -2.02B |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | 61.90% |
Pretax Margin | 61.49% |
Profit Margin | 45.51% |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.85, which amounts to a dividend yield of 3.67%.
Dividend Per Share | 0.85 |
Dividend Yield | 3.67% |
Dividend Growth (YoY) | 17.27% |
Years of Dividend Growth | 3 |
Payout Ratio | n/a |
Buyback Yield | -0.39% |
Shareholder Yield | 3.28% |
Earnings Yield | 9.45% |
FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | |
Lynch Upside | |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |